U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C15H15NO3
Molecular Weight 257.2851
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TOLMETIN

SMILES

Cc1ccc(cc1)C(=O)c2ccc(CC(=O)O)n2C

InChI

InChIKey=UPSPUYADGBWSHF-UHFFFAOYSA-N
InChI=1S/C15H15NO3/c1-10-3-5-11(6-4-10)15(19)13-8-7-12(16(13)2)9-14(17)18/h3-8H,9H2,1-2H3,(H,17,18)

HIDE SMILES / InChI
TOLECTIN is also indicated for treatment of juvenile rheumatoid arthritis. The mode of action of tolmetin is not known. However, studies in laboratory animals and man have demonstrated that the anti-inflammatory action of tolmetin is not due to pituitary-adrenal stimulation. Tolmetin inhibits prostaglandin synthetase in vitro and lowers the plasma level of prostaglandin E in man. This reduction in prostaglandin synthesis may be responsible for the anti-inflammatory action.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Tolmetin sodium

Approved Use

Carefully consider the potential benefits and risks of tolmetin sodium capsules and other treatment options before deciding to use tolmetin sodium capsules. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS). Tolmetin sodium capsules are indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. Tolmetin sodium capsules are indicated in the treatment of acute flares and the long-term management of the chronic disease. Tolmetin sodium capsules are also indicated for treatment of juvenile rheumatoid arthritis. The safety and effectiveness of tolmetin sodium capsules have not been established in pediatric patients under 2 years of age.

Launch Date

196473600000
Primary
Tolmetin sodium

Approved Use

Carefully consider the potential benefits and risks of tolmetin sodium capsules and other treatment options before deciding to use tolmetin sodium capsules. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS). Tolmetin sodium capsules are indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. Tolmetin sodium capsules are indicated in the treatment of acute flares and the long-term management of the chronic disease. Tolmetin sodium capsules are also indicated for treatment of juvenile rheumatoid arthritis. The safety and effectiveness of tolmetin sodium capsules have not been established in pediatric patients under 2 years of age.

Launch Date

196473600000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
29.3 μg/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TOLMETIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
50.5 μg × h/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TOLMETIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
0.83 h
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TOLMETIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
400 mg 3 times / day steady, oral
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
Other AEs: Nausea, Dyspepsia...
Other AEs:
Nausea (11%)
Dyspepsia (3-9)
Distress gastrointestinal (3-9)
Abdominal pain (3-9)
Diarrhea (3-9)
Flatulence (3-9)
Vomiting (3-9)
Constipation (1-3)
Gastritis (1-3)
Peptic ulcer (1-3)
Headache (3-9)
Asthenia (3-9)
Chest pain (1-3)
Blood pressure increased (3-9)
Edema (3-9)
Dizziness (3-9)
Drowsiness (3-9)
Depression (1-3)
Weight gain (3-9)
Weight loss (3-9)
Skin irritation (1-3)
Tinnitus (1-3)
Visual disturbance (1-3)
Blood urea nitrogen increased (1-3)
Urinary tract infection (1-3)
Gastrointestinal ulcer bleeding (<1%)
Bleeding gastrointestinal (<1%)
Perforation (<1%)
Glossitis (<1%)
Stomatitis (<1%)
Hepatitis (<1%)
Function liver abnormal (<1%)
Anaphylactoid reaction (<1%)
Fever (<1%)
Lymphadenopathy (<1%)
Serum sickness (<1%)
Hemolytic anemia (<1%)
Thrombocytopenia (<1%)
Granulocytopenia (<1%)
Agranulocytosis (<1%)
Urticaria (<1%)
Purpura (<1%)
Erythema multiforme (<1%)
Toxic epidermal necrolysis (<1%)
Hematuria (<1%)
Proteinuria (<1%)
Dysuria (<1%)
Renal failure (<1%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Blood urea nitrogen increased 1-3
400 mg 3 times / day steady, oral
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
Chest pain 1-3
400 mg 3 times / day steady, oral
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
Constipation 1-3
400 mg 3 times / day steady, oral
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
Depression 1-3
400 mg 3 times / day steady, oral
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
Gastritis 1-3
400 mg 3 times / day steady, oral
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
Peptic ulcer 1-3
400 mg 3 times / day steady, oral
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
Skin irritation 1-3
400 mg 3 times / day steady, oral
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
Tinnitus 1-3
400 mg 3 times / day steady, oral
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
Urinary tract infection 1-3
400 mg 3 times / day steady, oral
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
Visual disturbance 1-3
400 mg 3 times / day steady, oral
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
Nausea 11%
400 mg 3 times / day steady, oral
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
Abdominal pain 3-9
400 mg 3 times / day steady, oral
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
Asthenia 3-9
400 mg 3 times / day steady, oral
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
Blood pressure increased 3-9
400 mg 3 times / day steady, oral
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
Diarrhea 3-9
400 mg 3 times / day steady, oral
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
Distress gastrointestinal 3-9
400 mg 3 times / day steady, oral
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
Dizziness 3-9
400 mg 3 times / day steady, oral
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
Drowsiness 3-9
400 mg 3 times / day steady, oral
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
Dyspepsia 3-9
400 mg 3 times / day steady, oral
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
Edema 3-9
400 mg 3 times / day steady, oral
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
Flatulence 3-9
400 mg 3 times / day steady, oral
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
Headache 3-9
400 mg 3 times / day steady, oral
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
Vomiting 3-9
400 mg 3 times / day steady, oral
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
Weight gain 3-9
400 mg 3 times / day steady, oral
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
Weight loss 3-9
400 mg 3 times / day steady, oral
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
Agranulocytosis <1%
400 mg 3 times / day steady, oral
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
Anaphylactoid reaction <1%
400 mg 3 times / day steady, oral
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
Bleeding gastrointestinal <1%
400 mg 3 times / day steady, oral
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
Dysuria <1%
400 mg 3 times / day steady, oral
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
Erythema multiforme <1%
400 mg 3 times / day steady, oral
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
Fever <1%
400 mg 3 times / day steady, oral
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
Function liver abnormal <1%
400 mg 3 times / day steady, oral
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
Gastrointestinal ulcer bleeding <1%
400 mg 3 times / day steady, oral
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
Glossitis <1%
400 mg 3 times / day steady, oral
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
Granulocytopenia <1%
400 mg 3 times / day steady, oral
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
Hematuria <1%
400 mg 3 times / day steady, oral
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
Hemolytic anemia <1%
400 mg 3 times / day steady, oral
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
Hepatitis <1%
400 mg 3 times / day steady, oral
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
Lymphadenopathy <1%
400 mg 3 times / day steady, oral
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
Perforation <1%
400 mg 3 times / day steady, oral
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
Proteinuria <1%
400 mg 3 times / day steady, oral
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
Purpura <1%
400 mg 3 times / day steady, oral
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
Renal failure <1%
400 mg 3 times / day steady, oral
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
Serum sickness <1%
400 mg 3 times / day steady, oral
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
Stomatitis <1%
400 mg 3 times / day steady, oral
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
Thrombocytopenia <1%
400 mg 3 times / day steady, oral
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
Toxic epidermal necrolysis <1%
400 mg 3 times / day steady, oral
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
Urticaria <1%
400 mg 3 times / day steady, oral
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer



Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes [IC50 20.5 uM]
yes [IC50 494 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
yes
PubMed

PubMed

TitleDatePubMed
Immune hemolytic anemia associated with tolmetin and suprofen.
1989 Sep
Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients.
2001 Nov
Anti-inflammatory and antiplatelet effects of amtolmetin guacyl, a new gastroprotective non-steroidal anti-inflammatory drug.
2001 Sep
India ink staining after sodium dodecyl sulfate polyacrylamide gel electrophoresis and in conjunction with Western blots for peptide mapping by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.
2002
Three new vanadyl(IV) complexes with non-steroidal anti-inflammatory drugs (Ibuprofen, Naproxen and Tolmetin). Bioactivity on osteoblast-like cells in culture.
2002 Jan 1
Gastroprotective effects of amtolmetin guacyl: a new non-steroidal anti-inflammatory drug that activates inducible gastric nitric oxide synthase.
2002 Jun
Quantitation of tolmetin by high-performance liquid chromatography and method validation.
2003 Aug
Detection and disposition of tolmetin in the horse.
2003 Mar 26
Identification of zomepirac-S-acyl-glutathione in vitro in incubations with rat hepatocytes and in vivo in rat bile.
2003 Nov
Treatment of congenital nephrogenic diabetes insipidus by hydrochlorothiazide and cyclooxygenase-2 inhibitor.
2003 Oct
Nondestructive measurements of the compact strength and the particle-size distribution after milling of roller compacted powders by near-infrared spectroscopy.
2004 Apr
Spectroscopic behavior of copper complexes of nonsteroidal anti-inflammatory drugs.
2004 May-Jun 5
Kinetic studies on the intramolecular acyl migration of beta-1-O-acyl glucuronides: application to the glucuronides of (R)- and (S)-ketoprofen, (R)- and (S)-hydroxy-ketoprofen metabolites, and tolmetin by 1H-NMR spectroscopy.
2005 Jul
Prediction of genotoxicity of chemical compounds by statistical learning methods.
2005 Jun
Evidence for the bioactivation of zomepirac and tolmetin by an oxidative pathway: identification of glutathione adducts in vitro in human liver microsomes and in vivo in rats.
2006 Jan
Celosomy is associated with prenatal exposure to cyclooxygenase inhibitors.
2006 Mar
Non-steroidal anti-inflammatory agents, tolmetin and sulindac, inhibit liver tryptophan 2,3-dioxygenase activity and alter brain neurotransmitter levels.
2006 Nov 10
Non-steroidal anti-inflammatory agents, tolmetin and sulindac, attenuate oxidative stress in rat brain homogenate and reduce quinolinic acid-induced neurodegeneration in rat hippocampal neurons.
2006 Sep
One center's experience: the serology and drugs associated with drug-induced immune hemolytic anemia--a new paradigm.
2007 Apr
Polyproline-rod approach to isolating protein targets of bioactive small molecules: isolation of a new target of indomethacin.
2007 Jan 31
Improving adherence to medical regimens for juvenile rheumatoid arthritis.
2007 May 18
Role of biotransformation studies in minimizing metabolism-related liabilities in drug discovery.
2008
A novel high-throughput screening assay for putative antidiabetic agents through PPARalpha interactions.
2008 Oct
Nonsteroidal Anti-Inflammatory Drugs: A survey of practices and concerns of pediatric medical and surgical specialists and a summary of available safety data.
2010 Feb 4
Evaluation of Wound Healing Potential of Bauhinia purpurea Leaf Extracts in Rats.
2010 Jan
Effect of formulation and processing variables on the characteristics of tolmetin microspheres prepared by double emulsion solvent diffusion method.
2010 Jan
Unusual interleukin-1 and -6 expression in fetal cartilage is associated with placental abnormalities.
2010 Jan 1
Validation and clinical application of an LC-ESI-MS/MS method for simultaneous determination of tolmetin and MED5, the metabolites of amtolmetin guacil in human plasma.
2010 Oct
Diclofenac hypersensitivity: antibody responses to the parent drug and relevant metabolites.
2010 Oct 28
Effect of ketorolac and diclofenac on the impairment of endothelium-dependent relaxation induced by reactive oxygen species in rabbit abdominal aorta.
2010 Sep
A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans.
2014 Jan
Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.
2015 May 18
Patents

Sample Use Guides

For the relief of rheumatoid arthritis or osteoarthritis, the recommended starting dose
Route of Administration: Oral
Tolmetin inhibited the activity of human COX-1 and -2 with IC50 values of 0.35 and 0.82 uM, respectively
Name Type Language
TOLMETIN
HSDB   INN   MI   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
TOLMETIN [MI]
Common Name English
TOLMETIN [VANDF]
Common Name English
MCN-2559
Code English
TOLMETIN [INN]
Common Name English
TOLMETIN [HSDB]
Common Name English
TOLMETIN [USAN]
Common Name English
TOLMETIN [WHO-DD]
Common Name English
Classification Tree Code System Code
NDF-RT N0000000160
Created by admin on Sat Jun 26 02:15:39 UTC 2021 , Edited by admin on Sat Jun 26 02:15:39 UTC 2021
WHO-VATC QM01AB03
Created by admin on Sat Jun 26 02:15:39 UTC 2021 , Edited by admin on Sat Jun 26 02:15:39 UTC 2021
WHO-VATC QM02AA21
Created by admin on Sat Jun 26 02:15:39 UTC 2021 , Edited by admin on Sat Jun 26 02:15:39 UTC 2021
WHO-ATC M01AB03
Created by admin on Sat Jun 26 02:15:39 UTC 2021 , Edited by admin on Sat Jun 26 02:15:39 UTC 2021
WHO-ATC M02AA21
Created by admin on Sat Jun 26 02:15:39 UTC 2021 , Edited by admin on Sat Jun 26 02:15:39 UTC 2021
NCI_THESAURUS C257
Created by admin on Sat Jun 26 02:15:39 UTC 2021 , Edited by admin on Sat Jun 26 02:15:39 UTC 2021
LIVERTOX 978
Created by admin on Sat Jun 26 02:15:39 UTC 2021 , Edited by admin on Sat Jun 26 02:15:39 UTC 2021
NDF-RT N0000175722
Created by admin on Sat Jun 26 02:15:39 UTC 2021 , Edited by admin on Sat Jun 26 02:15:39 UTC 2021
NDF-RT N0000175721
Created by admin on Sat Jun 26 02:15:39 UTC 2021 , Edited by admin on Sat Jun 26 02:15:39 UTC 2021
Code System Code Type Description
HSDB
3403
Created by admin on Sat Jun 26 02:15:39 UTC 2021 , Edited by admin on Sat Jun 26 02:15:39 UTC 2021
PRIMARY
NCI_THESAURUS
C29503
Created by admin on Sat Jun 26 02:15:39 UTC 2021 , Edited by admin on Sat Jun 26 02:15:39 UTC 2021
PRIMARY
ChEMBL
CHEMBL1020
Created by admin on Sat Jun 26 02:15:39 UTC 2021 , Edited by admin on Sat Jun 26 02:15:39 UTC 2021
PRIMARY
DRUG BANK
DB00500
Created by admin on Sat Jun 26 02:15:39 UTC 2021 , Edited by admin on Sat Jun 26 02:15:39 UTC 2021
PRIMARY
WIKIPEDIA
TOLMETIN
Created by admin on Sat Jun 26 02:15:39 UTC 2021 , Edited by admin on Sat Jun 26 02:15:39 UTC 2021
PRIMARY
MESH
D014046
Created by admin on Sat Jun 26 02:15:39 UTC 2021 , Edited by admin on Sat Jun 26 02:15:39 UTC 2021
PRIMARY
IUPHAR
7311
Created by admin on Sat Jun 26 02:15:39 UTC 2021 , Edited by admin on Sat Jun 26 02:15:39 UTC 2021
PRIMARY
EPA CompTox
26171-23-3
Created by admin on Sat Jun 26 02:15:39 UTC 2021 , Edited by admin on Sat Jun 26 02:15:39 UTC 2021
PRIMARY
DRUG CENTRAL
2699
Created by admin on Sat Jun 26 02:15:39 UTC 2021 , Edited by admin on Sat Jun 26 02:15:39 UTC 2021
PRIMARY
PUBCHEM
5509
Created by admin on Sat Jun 26 02:15:39 UTC 2021 , Edited by admin on Sat Jun 26 02:15:39 UTC 2021
PRIMARY
RXCUI
10636
Created by admin on Sat Jun 26 02:15:39 UTC 2021 , Edited by admin on Sat Jun 26 02:15:39 UTC 2021
PRIMARY RxNorm
INN
2861
Created by admin on Sat Jun 26 02:15:39 UTC 2021 , Edited by admin on Sat Jun 26 02:15:39 UTC 2021
PRIMARY
CAS
26171-23-3
Created by admin on Sat Jun 26 02:15:39 UTC 2021 , Edited by admin on Sat Jun 26 02:15:39 UTC 2021
PRIMARY
MERCK INDEX
M10947
Created by admin on Sat Jun 26 02:15:39 UTC 2021 , Edited by admin on Sat Jun 26 02:15:39 UTC 2021
PRIMARY Merck Index
EVMPD
SUB11162MIG
Created by admin on Sat Jun 26 02:15:39 UTC 2021 , Edited by admin on Sat Jun 26 02:15:39 UTC 2021
PRIMARY
LACTMED
Tolmetin
Created by admin on Sat Jun 26 02:15:39 UTC 2021 , Edited by admin on Sat Jun 26 02:15:39 UTC 2021
PRIMARY
ECHA (EC/EINECS)
247-497-2
Created by admin on Sat Jun 26 02:15:39 UTC 2021 , Edited by admin on Sat Jun 26 02:15:39 UTC 2021
PRIMARY
FDA UNII
D8K2JPN18B
Created by admin on Sat Jun 26 02:15:39 UTC 2021 , Edited by admin on Sat Jun 26 02:15:39 UTC 2021
PRIMARY